Company intelligence / Profile preview

GNQ Insilico

Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

GNQ Insilico is a South Korean biotechnology company specializing in AI-driven drug discovery and development. The company utilizes its proprietary GNQ-AI platform to accelerate the identification and optimization of novel small molecule therapeutics, primarily focusing on oncology. Their pipeline includes selective inhibitors targeting cyclin-dependent kinases and PARP enzymes, aimed at treating various solid tumors and hematological malignancies. By integrating advanced computational modeling with biological validation, GNQ Insilico seeks to improve the efficiency and success rate of early-stage drug development.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on GNQ Insilico.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GNQ Insilico.

Explore the full profile